Celcuity LLC (CELC NASDAQ) stock market data APIs
$108.913
-2.49(-2.3%)
as of February 9, 2026
Try our APIs with
free plan!
Celcuity LLC Financial Data Overview
Price chart is built with
Anychart
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing of CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.
Prev. Close
108.913
Open
106.4265
High
110.5079
Low
105.7565
52 wk Range
7.575-120.315
Market Cap
4 993 M
Shares Outstanding
46 271 K
EPS
-0.78
Beta
0.382
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Celcuity LLC (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Celcuity LLC data using free add-ons & libraries
Get Celcuity LLC Fundamental Data
Celcuity LLC Fundamental data includes:
- Net Revenue:
- EBITDA: -159 268 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: -0.88
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Celcuity LLC News
New
Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump
Key Points David Dalvey sold 20,000 shares indirectly on Jan. 27, 2026 for a transaction value of ~$2.4 million, at a weighted average price of $120.03 per share. The transaction represented 18.18% o...
Oppenheimer Notes Relay Therapeutics (RLAY) Pipeline Strength in Mutant-Selective Inhibitors
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Relay Therapeutics, Inc. (NASDAQ:RLAY) is the next best biotech stock on our list. TheFly reported on January 26 that O...
Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances
Apis Capital Advisors’ Apis Flagship Fund released its Q4 2025 investor letter. A copy of the letter can be downloaded here. Apis Flagship Fund delivered strong performance in the fourth quarter of ...
FDA Accepts Celcuity's NDA For Gedatolisib In HR+, HER2- Advanced Breast Cancer
(RTTNews) - Celcuity Inc. (CELC), a clinical-stage biotechnology company, said on Tuesday that the U.S. Food and Drug Administration has accepted for filing its New Drug Application for gedatolisib in...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
